Efficacy and Safety of Suprachoroidal Triamcinolone Acetonide in Mixed Etiology Non-Infectious Cystoid Macular Edema

Purpose: To assess the efficacy and safety of suprachoroidal triamcinolone acetonide (SCS-TA) in the management of non-infectious cystoid macular edema (CME) of various etiologies. Methods: Retrospective observational study of 61 eyes of 56 patients with non-infectious CME who received SCS-TA injection. Primary outcomes were treatment response, central subfield thickness (CST), visual acuity (VA) and intraocular pressure (IOP) at baseline, one-month, and three months post-injection. Results: CME etiology included post-operative, uveitis, diabetes mellitus, and retinal vein occlusion. Complete resolution of CME occurred in 34 eyes (58.6%) at 1 month and 23 eyes (50.0%) at 3 months. Median CST improved from 430.0 µm (IQR, 366.0-547.5) to 297.0 µm (IQR, 277.0-392.0) at 1 month (p<0.001) and 326.5 µm (IQR, 263.9-380.6) at 3 months (p<0.001). VA improved from logMAR 0.60 (IQR, 0.40-0.88) 20/80 at baseline to 0.48 (IQR, 0.30-0.70) 20/60 at 1 month (p=0.002) and logMAR 0.44 (IQR, 0.18-0.88) 20/60 at 3 months (p=0.019). Significant IOP elevation was noted in 7 eyes (11.5%) overall, with no occurrences of infection, cataract progression, or suprachoroidal hemorrhage. Conclusion: SCS-TA demonstrated significant anatomical and functional improvements in eyes with non-infectious CME and a reassuring side effect profile.